Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · Biotech & pharma
MIAMI, August 25, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC).
Aug 25 · 22:00·Business Wire
Finance · Biotech & pharma
New York, New York--(August 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
Aug 25 · 21:44·Newsfile
Education · Biotech & pharma
WASHINGTON, Aug. 25, 2026 -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has welcomed the announcement that the University of Miami has gifted the federal government its 1994 ibogaine Investigational New Drug (IND) application.
Aug 25 · 20:49·GlobeNewswire
Finance · Biotech & pharma
NOVATO, Calif., Aug. 25, 2026 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Aug 25 · 20:30·GlobeNewswire
Finance · Healthcare
SAN DIEGO, August 25, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET.
Aug 25 · 20:05·Business Wire
Healthcare · Biotech & pharma
Rockville, Maryland--(August 25, 2026) - American Gene Technologies, is a clinical-stage biotechnology company developing AGT103-T, a one-time gene-modified T-cell therapy that is the only program to demonstrate elimination of the HIV viral reservoir in humans., is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City. Drew Palin MD President AGT, will...
Aug 25 · 18:48·Newsfile
Finance · Biotech & pharma
New York, New York--(August 25, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us. You may also...
Aug 25 · 18:45·Newsfile
Finance · Biotech & pharma
BENSALEM, Pa., Aug. 25, 2026 -- Law Offices of Howard G. Smith continues its investigation on behalf of Sionna Therapeutics, Inc. (“Sionna” or the “Company”) (NASDAQ: SION) investors concerning the Company’s possible violations of federal securities laws.
Aug 25 · 18:00·GlobeNewswire
Healthcare · Logistics
New research finds neurologists anticipate meaningful durable remission in neuro-immune disease, while long-term safety, patient selection, and treatment logistics remain central to future uptake.
New research finds neurologists anticipate meaningful durable remission in neuro-immune disease, while long-term safety, patient selection, and treatment logistics remain central to future uptake.
Aug 25 · 15:13·GlobeNewswire
Finance · Healthcare
SAN CARLOS, Calif., August 25, 2026--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction,
Aug 25 · 14:40·Business Wire
Finance · Healthcare
VANCOUVER, British Columbia, Aug. 25, 2026 -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration (FDA) approval for two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA): Ziihera plus Tevimbra® (tislelizumab-jsgr) and fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+ and IHC 2+/ISH+), and Ziihera plus fluoropyrimidine- and platinum-containing chemotherapy (HER2+ IHC 3+).
Aug 25 · 14:23·GlobeNewswire
Finance · Biotech & pharma
Nika Pharmaceuticals, Inc. (OTCQB: NIKA) updates its shareholders regarding ongoing negotiations for up to 50 million USD and expected funding timeline.
Aug 25 · 14:13·GlobeNewswire